Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant capecitabine after curative resection for hepatocellular carcinoma
ACTRN12609000574246Phase 3Completed
- Sponsor
- Eastern Hepatobiliary Surgery Hospital
- Start
- Aug 2003
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of capecitabine in hepatocellular carcinoma (HCC) (2 arms), sponsored by Eastern Hepatobiliary Surgery Hospital. Primary endpoints: Time to recurrence and Overall survival. Started Aug 2003; status: completed.
02
Drugs
capecitabine
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ACTRN12609000574246.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12609000574246.